Quick Answer
LIFECORE BIOMEDICAL, INC. \DE\ reported Total Revenue of $524.23 million for fiscal year 2018.
LIFECORE BIOMEDICAL, INC. \DE\ — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$38.72M -422.3% |
$12.01M +112.1% |
-$99.56M +14.7% |
-$116.72M -261.4% |
-$32.29M +15.4% |
-$38.19M -9392.2% |
| Diluted EPS | -$1.27 -484.8% |
$0.33 +109.9% |
-$3.32 +16.4% |
-$3.97 -260.9% |
-$1.10 +16.0% |
-$1.31 -13200.0% |
| Total Assets | $239.34M -5.8% |
$253.96M +7.3% |
$236.66M -27.0% |
$324.24M -36.0% |
$506.86M +72.7% |
$293.50M |
| Cash and Equivalents | $8.27M -2.3% |
$8.46M +186.8% |
$2.95M +167.9% |
$1.10M -40.6% |
$1.85M +414.7% |
$360.0K |
| Long-Term Debt | — | $100.82M +1.9% |
$98.90M +24.2% |
$79.60M -45.1% |
$145.05M +43.1% |
$101.36M +16.3% |
| Stockholders Equity | $1.34M -88.2% |
$11.31M -67.7% |
$35.02M -75.4% |
$142.56M -29.5% |
$202.20M -12.0% |
$229.84M |
| R&D Expense | $8.26M -3.7% |
$8.57M -1.8% |
$8.74M +11.4% |
$7.84M +17.3% |
$6.68M -11.8% |
$7.58M -33.9% |
| Operating Income | -$17.25M -95.0% |
-$8.84M +59.4% |
-$21.80M -84.9% |
-$11.79M -33.6% |
-$8.82M +65.9% |
-$25.88M -572.6% |
| Gross Profit | $40.30M -3.7% |
$41.85M +49.5% |
$27.98M -28.4% |
$39.07M +0.3% |
$38.94M -1.1% |
$39.39M -51.4% |
| Shares Outstanding | 37.03M +21.1% |
30.56M +0.8% |
30.32M +2.7% |
29.51M +0.6% |
29.33M +0.4% |
29.22M +0.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | February 28, 2018 | $149.32M | +9.3% | +9.4% |
| Net Income | September 30, 2025 | -$9.99M | — | +32.4% |
| Diluted EPS | September 30, 2025 | -$0.29 | — | +38.3% |
| Total Assets | September 30, 2025 | $235.20M | — | -1.7% |
| Cash and Equivalents | September 30, 2025 | $18.86M | — | +128.1% |
| Long-Term Debt | November 30, 2024 | $110.53M | +20.0% | +4.7% |
| Stockholders Equity | September 30, 2025 | -$10.54M | — | -1123.8% |
| R&D Expense | September 30, 2025 | $1.96M | — | -4.0% |
| Operating Income | September 30, 2025 | -$3.07M | — | +66.0% |
| Gross Profit | September 30, 2025 | $7.79M | — | -20.9% |
| Shares Outstanding | September 30, 2025 | 37.47M | — | +1.2% |
- LIFECORE BIOMEDICAL, INC. \DE\ reported Total Revenue of $524.23 million for fiscal year 2018.
- LIFECORE BIOMEDICAL, INC. \DE\ showed an increase of +11.6% in Total Revenue compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Net Income of -$38.72 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -422.3% in Net Income compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -484.8% in Diluted EPS compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Total Assets of $239.34 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -5.8% in Total Assets compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Cash and Equivalents of $8.27 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -2.3% in Cash and Equivalents compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Long-Term Debt of $100.82 million for fiscal year 2024.
- LIFECORE BIOMEDICAL, INC. \DE\ showed an increase of +19.7% in Long-Term Debt compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Stockholders Equity of $1.34 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -88.2% in Stockholders Equity compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported R&D Expense of $8.26 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -3.7% in R&D Expense compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Operating Income of -$17.25 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -95.0% in Operating Income compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Gross Profit of $40.30 million for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed a decrease of -3.7% in Gross Profit compared to the prior fiscal year.
- LIFECORE BIOMEDICAL, INC. \DE\ reported Shares Outstanding of 37.03 million shares for fiscal year 2025.
- LIFECORE BIOMEDICAL, INC. \DE\ showed an increase of +21.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: